TAMPA, FL / ACCESSWIRE / June 16, 2015 / Wiand Guerra King (“WGK”), a Florida-based financial services and complex litigation law firm with a national reputation, is pleased to announce that Cameron G. Stout, Esq. has joined the firm as Senior Counsel with responsibility for the firm’s newly established Palo Alto Office. Mr. Stout has spent 30 years litigating for major financial services companies. His practice also includes employment law and commercial litigation. Firm Chairman Burton Wiand said, “Cam brings tremendous benefits to WGK – a physical presence in California and the addition of one of the best known financial services and commercial litigators in the State. We are thrilled to have a lawyer with his expertise and reputation join WGK.”

In addition to coordinating the firm’s litigation activities on the West Coast, Mr. Stout will serve as a Principal of WGK-ADR, the firm’s alternative dispute resolution practice, providing mediation and arbitration services throughout the United States. Mr. Stout is a certified mediator who will mediate and arbitrate securities and employment cases, and general commercial litigation, as well as family law, estate and elder abuse disputes.

Mr. Stout is admitted to practice in the State of California, and before the District Courts of the Northern and Central Districts of California. He may be contacted at 650.800.7636 (work), 415.595.5409 (cell), and at cstout@wiandlaw.com.

WGK advises a wide array of clients regarding business, litigation, regulatory and compliance issues. For more information, contact Burt Wiand at bwiand@wiandlaw.com or George Guerra at gguerra@wiandlaw.com.

CONTACT:

Burton W. Wiand
George L. Guerra

WIAND GUERRA KING P.A.

(813) 347-5100
bwiand@wiandlaw.com
gguerra@wiandlaw.com

SOURCE: Wiand Guerra King P.A.

ReleaseID: 429890

CORAL GABLES, FL / ACCESSWIRE / June 16, 2015 / More states are jumping on board the cannabis train and this industry has certainly begun to evolve since Colorado first came online as America’s original legal state. Despite the recent uproar concerning the decision for business owners not to condone cannabis use (medical or otherwise), the market continues to take a liking to this industry because it is, in fact, just beginning to blossom. Aside from popular belief, this space isn’t full of growers alone, there is an entire economy growing around the idea. Businesses are sprouting up with ideas from anything like cannabis vacation destinations to hemp infused beverages and anything in between. Companies like FBEC Worldwide (PINKSHEETS: FBEC), the Maryjane Group (OTCQB: MJMJ) and GrowBLOX Sciences, Inc. (OTCQB: GBLX) have all begun to see interest building around their novel concepts.

FBEC Worldwide has been gaining traction since May. From low prices of $0.004 to highs of $0.12, this cannabis stock has run up more than 3,100%. FBEC has restructured management and placed a new CEO at the helm. Under the new regime, Robert Sand, CEO of FBEC, has begun to clean up the company’s share structure after having previously announced that management will focus on cleaning up unfavorable financing. Furthermore, FBEC has moved forward with the development of its proprietary hemp infused energy drinks. Last week the company announced that it has entered into a commercial supply agreement with J&D Labs, Inc. to manufacture hemp-based nutraceuticals. “We are making a commitment with J&D Labs that would meet our longer term objectives in manufacturing our future hemp-based nutraceutical products. On a regular basis, we, along with leading researchers around the world, regularly uncover additional uses and benefits of hemp as a supplement and additive,” stated Sands.

The Maryjane Group has also begun to gain notoriety within this growing market after announcing that it will be offering the first Cannabis Resort to open in the US. Labeled “CannaCamp” this destination combines recreational cannabis use and education with a traditional ranch experience to create the country’s “first-ever cannabis resort. CannaCamp is now accepting reservations for this year’s summer season, July 1 – October 31.” In response to this, the market has briefly exploded with interest as shares jumped from $0.0015 to highs of $0.0137. During the week of June 15, MJMJ stock price has settled around $0.003 for the first half of the week leading up to the Father’s Day weekend.

Finally, GrowBlox Sciences has begun to find reinterest in the stock market. A company that focuses on pharmaceutical grade cannabinoid therapies recently announced that it has received a $1.75 million funding commitment to enable GrowBLOX to complete construction and set-up operations at their MME Cultivation Facility in Las Vegas, Nevada. Pacific Leaf Ventures, LP has provided both the capital infusion and a license for their intellectual property including recognizable brand names of cannabis and proprietary know-how for cultivation and cannabis extractions. This news has sparked more action for the stock. After falling to lows of $0.151 in March, shares of GBLX have jumped more than 100% and on some days, nearly 400% as the stock has climbed as high as $0.74 in May.

About marijuanastocks.com

MarijuanaStocks.com is the leading web destination for all things cannabis. Investors can find marijuana related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MAPH Enterprises LLC which owns www.MarijuanaStocks.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.

MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Contact Information:

marijuanastocks.com
800-539-4313
pr@marijuanastocks.com

SOURCE: MarijuanaStocks.com

ReleaseID: 429888

MONROE, MI / ACCESSWIRE / June 16, 2015 / La-Z-Boy Incorporated (NYSE: LZB) will host a conference call and live webcast to discuss the results of the fourth quarter and fiscal year 2015, to be held Wednesday, June 17, 2015 at 8:30 AM Eastern Time.

To participate in this event, dial 877-407-0778 domestically, or 201-689-8565 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at www.investorcalendar.com/IC/CEPage.asp?ID=174035 as well as via the La-Z-Boy Incorporated website (http://investors.la-z-boy.com/phoenix.zhtml?c=92596&p=irol-IRHome).

If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com/ or http://investors.la-z-boy.com/phoenix.zhtml?c=92596&p=irol-IRHome.

You may access the teleconference replay by dialing 877-660-6853 domestically or 201-612-7415 internationally, referencing conference ID # 13610152. The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern on June 24, 2015.

About La-Z-Boy Incorporated

La-Z-Boy Incorporated is one of the world’s leading residential furniture producers, marketing furniture for every room of the home. The La-Z-Boy Upholstery segment companies are England and La-Z-Boy. The Casegoods segment consists of three brands: American Drew, Hammary, and Kincaid. The company-owned Retail segment includes 108 of the 326 La-Z-Boy Furniture Galleries(R) stores.

The corporation’s branded distribution network is dedicated to selling La-Z-Boy Incorporated products and brands, and includes 326 stand-alone La-Z-Boy Furniture Galleries(R) stores and 567 independent Comfort Studios(R) locations, in addition to in-store gallery programs for the company’s Kincaid and England operating units. Additional information is available at http://www.la-z-boy.com/.

SOURCE: La-Z-Boy Incorporated

ReleaseID: 429849

WINDSOR, ON / ACCESSWIRE / June 16, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known, Biotech stocks making news and subsequent market moves, would like to report on the seldom huge potential of the OTC market when used as a proper stepping-stone to a national stock exchange.

Very seldom do you see long-term success in the sometimes scary OTC market. One might gauge long-term success as assembling a world class management team, raising some capital on not-so-good terms, and bringing a business plan to the point where it’s considered a valuable asset. Down this road, there are many more things that can go wrong than can go right. The proverbial pot of gold at the end of the rainbow would be the infamous “up-listing” to the NASDAQ or the NYSE-by way of achieving the aforementioned goals, but also quantifiable goals like share price and book value increases. It’s not an easy task. 

The biggest success story in this category in recent history (there are a few more we may detail in later articles) is without a doubt Advaxis Inc. (NASDAQ: ADXS). It helps that ADXS in in the white-hot immunotherapy space, but in all fairness, everything under the healthcare umbrella is outperforming. Time to look for another potential “Advaxis”; all you have to do is find strong companies in earlier stages of their research (and have a bit of luck). Investors who bought Advaxis back when it was on the OTC exchange 2 years ago have been treated to gains in the 500% – 1,000% range. ADXS is having great success with their main drug in clinical trials indicated to treat cervical cancer.

Propanc Health Group (OTC: PPCH) is a Company we’ve been mentioning since it was $0.0038; it’s now a staggering 2,700% higher in the realm of $0.10-investors who invested $10,000 may have over a quarter million dollars now. The Company just had research coverage (http://www.seethruequity.com/#!ppch/c5jp) giving them a $1.52 price target which is 1,400% higher than the current price. This may be aggressive, but they are working on a treatment for aggressive cancers, such as pancreatic, which currently have limited treatment options, as well as cancers with large unmet medical need, such as colorectal cancer, where a high mortality rate still exists. Technicians looking at the stock chart may argue that the supply of sellers in the $0.10 range is wearing thin, and could pose a potential break-out opportunity for traders.

Looking even further in the rear-view mirror we look for promising companies / business plans, with stand-out management teams who can raise capital for their ideas-in this instance we look for stocks which haven’t had a big run yet, as the initial breakout is where the lion’s share of profits are usually made. Falling into this category The Wealthy Biotech Trader is alerting Investors of a catalyst prone stock PositiveID Corp. (OTC: PSID). Provided the Company keeps making progress on their new Firefly Dx unit, we feel this could be a big winner. Readers should take a minute to read this brief overview of PSID and its star product, the Firefly: http://goo.gl/g4K3WT. There are several potential catalysts that could move this stock upwards, and we will keep readers apprised via Twitter and Facebook-we also release research notes via press release, so put it on your watch list of trades to make. The shares are trading at a paltry $0.016 giving the company a market value of only $4.7 Million.

Another noteworthy company in the healthcare space, more specifically in the biotech space, is Taplmmune (OTC: TPIV). TPIV is also in the super-hot space of immunotherapy like Advaxis (NASDAQ: ADXS). Being in the immuno-oncology space may be one of the main reasons for the stock’s recent aggressive move upwards, but could also be attributed to some of the positive news the company has updated investors on upcoming phase II trials for their lead product(s) TPIV100/200. The Company’s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by the modulation of TAP (Transporter associated with Antigen Processing).

The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports / updates / news through Twitter and Facebook as well as newswire. 

GET BREAKING NEWS FROM US:

Follow us on Twitter: @Wealthy_VC
Like us on Facebook: www.facebook.com/WealthyVC
Email: Info@WealthyVentureCapitalist.com

This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.

The Wealthy Biotech Trader’s parent company has been and will continue to be compensated $25,000 per month by PositiveID. The Wealthy Biotech Trader’s controlling parent company has also been compensated $62,500 by PositiveID in the form of a convertible note and readers should understand that they will convert this note into common shares and sell them into the market as soon as the statutory 144 hold period has lapsed. The Wealthy Biotech Trader’s parent company has been and will be compensated roughly $5,000 per month by Propanc Heath Group. The Wealthy Biotech Trader’s controlling parent company has also been compensated $60,000 by Propanc Heath Group in the form of a convertible note and readers should understand that they will convert this note into common shares sell them into the market as soon as the statutory 144 hold period has lapsed. 

Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.

SOURCE: The Wealthy Biotech Trader

ReleaseID: 429877